Optimal timing of influenza vaccination among patients with
acute myocardial infarction - Findings from the IAMI trial

J 2023

Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial

AKHTAR, Zubair, Matthias GOTBERG, David ERLINGE, Evald H CHRISTIANSEN, Keith G OLDROYD et. al.

Základní údaje

Originální název

Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial

Autoři

AKHTAR, Zubair, Matthias GOTBERG, David ERLINGE, Evald H CHRISTIANSEN, Keith G OLDROYD, Zuzana MOTOVSKA, Andrejs ERGLIS, Ota HLINOMAZ (203 Česká republika, domácí), Lars JAKOBSEN, Thomas ENGSTROM, Lisette O JENSEN, Christian O FALLESEN, Svend E JENSEN, Oskar ANGERAS, Fredrik CALAIS, Amra KAREGREN, Jorg LAUERMANN, Arash MOKHTARI, Johan NILSSON, Jonas PERSSON, Abu K M M ISLAM, Afzalur RAHMAN, Fazila MALIK, Sohel CHOUDHURY, Timothy COLLIER, Stuart J POCOCK, John PERNOW, Chandini R MACINTYRE a Ole FROBERT

Vydání

Vaccine, Oxford, ELSEVIER SCI LTD, 2023, 0264-410X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.500 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133729

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.vaccine.2023.10.028

UT WoS

001120169600001

Klíčová slova anglicky

Influenza vaccination; Optimal timing; Vaccine effectiveness; Percutaneous coronary intervention; Myocardial infarction

Štítky

14110132, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 3. 2024 08:19, Mgr. Tereza Miškechová

Anotace

V originále

Influenza vaccination reduces the risk of adverse cardiovascular events. The IAMI trial randomly assigned 2571 patients with acute myocardial infarction (AMI) to receive influenza vaccine or saline placebo during their index hospital admission. It was conducted at 30 centers in 8 countries from October 1, 2016 to March 1, 2020. In this post-hoc exploratory sub-study, we compare the trial outcomes in patients receiving early season vaccination (n = 1188) and late season vaccination (n = 1344). The primary endpoint was the composite of all-cause death, myocardial infarction (MI), or stent thrombosis at 12 months. The cumulative incidence of the primary and key secondary endpoints by randomized treatment and early or late vaccination was estimated using the Kaplan-Meier method. In the early vaccinated group, the primary composite endpoint occurred in 36 participants (6.0%) assigned to influenza vaccine and 49 (8.4%) assigned to placebo (HR 0.69; 95% CI 0.45 to 1.07), compared to 31 participants (4.7%) assigned to influenza vaccine and 42 (6.2%) assigned to placebo (HR 0.74; 95% CI 0.47 to 1.18) in the late vaccinated group (P = 0.848 for interaction on HR scale at 1 year). We observed similar estimates for the key secondary endpoints of all-cause death and CV death. There was no statistically significant difference in vaccine effectiveness against adverse cardiovascular events by timing of vaccination. The effect of vaccination on all-cause death at one year was more pronounced in the group receiving early vaccination (HR 0.50; 95% CI, 0.29 to 0.86) compared late vaccination group (HR 0.75; 35% CI, 0.40 to 1.40) but there was no statistically significant difference between these groups (Interaction P = 0.335). In conclusion, there is insufficient evidence from the trial to establish whether there is a difference in efficacy between early and late vaccination but regardless of vaccination timing we strongly recommend influenza vaccination in all patients with cardiovascular diseases.

Citovat

AKHTAR, Zubair, Matthias GOTBERG, David ERLINGE, Evald H CHRISTIANSEN, Keith G OLDROYD, Zuzana MOTOVSKA, Andrejs ERGLIS, Ota HLINOMAZ, Lars JAKOBSEN, Thomas ENGSTROM, Lisette O JENSEN, Christian O FALLESEN, Svend E JENSEN, Oskar ANGERAS, Fredrik CALAIS, Amra KAREGREN, Jorg LAUERMANN, Arash MOKHTARI, Johan NILSSON, Jonas PERSSON, Abu K M M ISLAM, Afzalur RAHMAN, Fazila MALIK, Sohel CHOUDHURY, Timothy COLLIER, Stuart J POCOCK, John PERNOW, Chandini R MACINTYRE a Ole FROBERT. Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial. Vaccine. Oxford: ELSEVIER SCI LTD, 2023, roč. 41, č. 48, s. 7159-7165. ISSN 0264-410X. Dostupné z: https://dx.doi.org/10.1016/j.vaccine.2023.10.028.

@article{2381677,
   author = {Akhtar, Zubair and Gotberg, Matthias and Erlinge, David and Christiansen, Evald H and Oldroyd, Keith G and Motovska, Zuzana and Erglis, Andrejs and Hlinomaz, Ota and Jakobsen, Lars and Engstrom, Thomas and Jensen, Lisette O and Fallesen, Christian O and Jensen, Svend E and Angeras, Oskar and Calais, Fredrik and Karegren, Amra and Lauermann, Jorg and Mokhtari, Arash and Nilsson, Johan and Persson, Jonas and Islam, Abu K M M and Rahman, Afzalur and Malik, Fazila and Choudhury, Sohel and Collier, Timothy and Pocock, Stuart J and Pernow, John and Macintyre, Chandini R and Frobert, Ole},
   article_location = {Oxford},
   article_number = {48},
   doi = {http://dx.doi.org/10.1016/j.vaccine.2023.10.028},
   keywords = {Influenza vaccination; Optimal timing; Vaccine effectiveness; Percutaneous coronary intervention; Myocardial infarction},
   language = {eng},
   issn = {0264-410X},
   journal = {Vaccine},
   title = {Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial},
   url = {https://www.sciencedirect.com/science/article/pii/S0264410X23012112?via%3Dihub},
   volume = {41},
   year = {2023}
}

TY  - JOUR
ID  - 2381677
AU  - Akhtar, Zubair - Gotberg, Matthias - Erlinge, David - Christiansen, Evald H - Oldroyd, Keith G - Motovska, Zuzana - Erglis, Andrejs - Hlinomaz, Ota - Jakobsen, Lars - Engstrom, Thomas - Jensen, Lisette O - Fallesen, Christian O - Jensen, Svend E - Angeras, Oskar - Calais, Fredrik - Karegren, Amra - Lauermann, Jorg - Mokhtari, Arash - Nilsson, Johan - Persson, Jonas - Islam, Abu K M M - Rahman, Afzalur - Malik, Fazila - Choudhury, Sohel - Collier, Timothy - Pocock, Stuart J - Pernow, John - Macintyre, Chandini R - Frobert, Ole
PY  - 2023
TI  - Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial
JF  - Vaccine
VL  - 41
IS  - 48
SP  - 7159-7165
EP  - 7159-7165
PB  - ELSEVIER SCI LTD
SN  - 0264410X
KW  - Influenza vaccination
KW  - Optimal timing
KW  - Vaccine effectiveness
KW  - Percutaneous coronary intervention
KW  - Myocardial infarction
UR  - https://www.sciencedirect.com/science/article/pii/S0264410X23012112?via%3Dihub
N2  - Influenza vaccination reduces the risk of adverse cardiovascular events. The IAMI trial randomly assigned 2571 patients with acute myocardial infarction (AMI) to receive influenza vaccine or saline placebo during their index hospital admission. It was conducted at 30 centers in 8 countries from October 1, 2016 to March 1, 2020. In this post-hoc exploratory sub-study, we compare the trial outcomes in patients receiving early season vaccination (n = 1188) and late season vaccination (n = 1344). The primary endpoint was the composite of all-cause death, myocardial infarction (MI), or stent thrombosis at 12 months. The cumulative incidence of the primary and key secondary endpoints by randomized treatment and early or late vaccination was estimated using the Kaplan-Meier method. In the early vaccinated group, the primary composite endpoint occurred in 36 participants (6.0%) assigned to influenza vaccine and 49 (8.4%) assigned to placebo (HR 0.69; 95% CI 0.45 to 1.07), compared to 31 participants (4.7%) assigned to influenza vaccine and 42 (6.2%) assigned to placebo (HR 0.74; 95% CI 0.47 to 1.18) in the late vaccinated group (P = 0.848 for interaction on HR scale at 1 year). We observed similar estimates for the key secondary endpoints of all-cause death and CV death. There was no statistically significant difference in vaccine effectiveness against adverse cardiovascular events by timing of vaccination. The effect of vaccination on all-cause death at one year was more pronounced in the group receiving early vaccination (HR 0.50; 95% CI, 0.29 to 0.86) compared late vaccination group (HR 0.75; 35% CI, 0.40 to 1.40) but there was no statistically significant difference between these groups (Interaction P = 0.335). In conclusion, there is insufficient evidence from the trial to establish whether there is a difference in efficacy between early and late vaccination but regardless of vaccination timing we strongly recommend influenza vaccination in all patients with cardiovascular diseases.
ER  -

AKHTAR, Zubair, Matthias GOTBERG, David ERLINGE, Evald H CHRISTIANSEN, Keith G OLDROYD, Zuzana MOTOVSKA, Andrejs ERGLIS, Ota HLINOMAZ, Lars JAKOBSEN, Thomas ENGSTROM, Lisette O JENSEN, Christian O FALLESEN, Svend E JENSEN, Oskar ANGERAS, Fredrik CALAIS, Amra KAREGREN, Jorg LAUERMANN, Arash MOKHTARI, Johan NILSSON, Jonas PERSSON, Abu K M M ISLAM, Afzalur RAHMAN, Fazila MALIK, Sohel CHOUDHURY, Timothy COLLIER, Stuart J POCOCK, John PERNOW, Chandini R MACINTYRE a Ole FROBERT. Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial. \textit{Vaccine}. Oxford: ELSEVIER SCI LTD, 2023, roč.~41, č.~48, s.~7159-7165. ISSN~0264-410X. Dostupné z: https://dx.doi.org/10.1016/j.vaccine.2023.10.028.

Podrobný výpis o publikaci